Contraindicated. Coadministration of doravirine with a strong CYP3A inducer may possibly decrease doravirine plasma concentrations and/or effects. Probable for lack of virologic response and feasible resistance to doravirine.pentobarbital will lower the level or outcome of lonafarnib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contr